Local view for "http://purl.org/linkedpolitics/eu/plenary/2014-04-02-Speech-3-047-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20140402.15.3-047-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spoken text |
"Mr President, I would like to thank all the speakers who have contributed. Our prime concern, as Commissioner Borg said, is the patient; it has got to be the patient. This regulation answers many questions. We have less bureaucracy, with a single portal and cross-border trials, for which you only need make one application instead of several. That will make everything much easier and much quicker, while keeping patients’ safety at the heart of things. This will also see new and better medicines being brought forward, and that is what is important in this regulation. We have also got increased transparency, and all the clinical trial reports and data will be published, even for unsuccessful trials. That is really important. It is good for science, it is good for patients’ safety and it is good for public trust.
I want to say a little bit about the support that we have had from everybody. I cannot remember dealing with any legislation in this Parliament where we have had so much cooperation and goodwill. We have had the support of the rapporteurs, who have worked very closely together, and the support of the Commission and the Council. Let us also mention the secretariat of the Committee on the Environment, Public Health and Food Safety, who did a fantastic job too. We have achieved a really good deal. We have worked with a strong spirit of cooperation and understanding. I wish that all legislation could be dealt with in that way."@en1
|
| lpv:spokenAs | |
| lpv:unclassifiedMetadata | |
| lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples